Source:http://linkedlifedata.com/resource/pubmed/id/16209432
Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions | |
pubmed:issue |
5
|
pubmed:dateCreated |
2005-10-7
|
pubmed:abstractText |
Whereas in Germany the development of the composition of Castellan's solution resulted in its replacement with a solution of basic fuchsine alone, on the other hand in the Czech Republic fuchsine was excluded from the composition of the preparation. It is therefore desirable to evaluate the composition of Castellan's solution according to the Czech Pharmacopoeia and fuchsine from the viewpoint of the therapeutic benefits and risks of the individual active ingredients.
|
pubmed:language |
cze
|
pubmed:journal | |
pubmed:citationSubset |
IM
|
pubmed:chemical | |
pubmed:status |
MEDLINE
|
pubmed:month |
Sep
|
pubmed:issn |
1210-7816
|
pubmed:author | |
pubmed:issnType |
Print
|
pubmed:volume |
54
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
199-200
|
pubmed:dateRevised |
2006-11-15
|
pubmed:meshHeading | |
pubmed:year |
2005
|
pubmed:articleTitle |
[The development of the composition of Castellan's solution].
|
pubmed:affiliation |
Veterinárni a farmaceutické univerzita Brno, Farmaceutická fakulta, Ustav chemických léciv. subertj@vfu.cz
|
pubmed:publicationType |
Journal Article,
English Abstract
|